Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Rhea-AI Summary
Vor Bio (NASDAQ:VOR), a clinical-stage biotech company focused on autoimmune disease treatments, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum. The company will engage in a fireside chat on Monday, September 15, 2025, from 4:00-4:25 pm ET in Track 1.
The virtual event will also include one-on-one meetings with investors. Both live webcast and replay of the fireside chat will be accessible through Vor Bio's investor relations website.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.
Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1
Location: Virtual
A live webcast and archived replay of the fireside chat will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
When is Vor Bio's fireside chat at the Stifel 2025 Virtual Immunology Forum?
How can investors access Vor Bio's Stifel 2025 Forum presentation?
What type of meetings will Vor Bio host at the Stifel 2025 Forum?
What is Vor Bio's focus as a clinical-stage biotech company?
